The clinical AI platform for longevity medicine in Spanish, proven daily in the founder's own practice.
Dr. Miguel Bravo, Founder. Plastic surgeon and longevity physician, licensed in Spain and Abu Dhabi.
Navigate with the arrow keys, the dots, or the arrows below
Thousands of clinics want to sell longevity care in Spanish, and the engine to power them does not exist.
Aesthetics, plastic-surgery and longevity clinics across Spain and Latin America want to enter metabolic and longevity care, and no Spanish-native clinical engine exists to power them. Meanwhile, premium patients in the UAE already pay for this care at researched market prices, proving the demand the engine serves. The gap is the combination.
No Spanish-native engine
US tools and clinics are English-only and US-centric: US units, US ranges, US assumptions that break on EU and LatAm lab reports. A language market of roughly 500 million people is an afterthought.
Clinics want in, without rails
Thousands of aesthetics, plastic-surgery and longevity clinics already serve the exact demographic, affluent and prevention-minded, and want to add metabolic and longevity care. They lack the engine, the protocols and the report depth, and the available tools stop at high/low flags.
The UAE proves patients pay
In Abu Dhabi and Dubai, premium patients pay researched market prices for longevity programs, and insurance excludes optimization care, so the market is pure cash-pay. The founder is licensed and practicing there. The demand the engine serves is already paying, in a market Longeva operates in.
Market-structure footnote: the EU also bans DTC prescription advertising, which keeps US ad-driven playbooks out of Europe. Useful context, not why Longeva wins. The combination lane is wide open.
B2B is the venture market: clinics across Spain and 20 LatAm countries. The UAE practice is the proof and the cash.
Two engines, two markets. The venture-scale market is B2B: clinics across Spain and some 20 Spanish-speaking countries in Latin America, at 59-169 EUR per month plus a custom Empresa tier. The proof-and-cash market is the UAE, where researched anchors already exist: King's College Hospital Dubai sells longevity programs at AED 17,500-32,500 (clinic package tiers as quoted, 2026). Every figure below is our own projection, not third-party data.
Sizing: founder estimates, June 2026. Presented as illustrative projections.
Incumbents validate demand on both sides, and nothing Spanish-native exists on the platform side.
Real incumbents, stated factually: they prove the demand and the premium price point. What none of them has is Longeva's combination.
Neolife
Premium age-management clinic group, 10+ years in operation, centers in Madrid, Barcelona and Marbella, now franchising to expand: biomarker panels, hormone optimization, longevity programs.
Clínica Neleva
Premium healthspan clinic in Madrid led by Dr. Durantez, one of Spain's best-known preventive-medicine physicians.
SHA Wellness
Destination luxury longevity and wellness: a different, high-end model that confirms the top of the market.
Signal: Melio, a direct-to-consumer blood-testing prevention startup in Spain and the UK, exited the consumer market in March 2024 and pivoted to B2B immunology biotech (IMU Biosciences). Our read: the closest DTC comp could not hold the consumer lane, the lane Longeva deliberately does not take.
The B2B lens: the only comparable clinician platform is NGM in the US, English-only. Nothing Spanish-native exists. The UAE lens: King's College Hospital Dubai and Clinique La Prairie validate the premium price anchor Longeva's practice prices against.
A units-aware clinical AI engine: optimal-range depth on any country's labs.
A B2B platform shipping now: the engine licenses to clinics from day one; none of them license theirs.
A surgeon-founder warm channel: Preop and SECPRE mean structurally lower CAC.
Asset-light, national from day one: their model is buildings; ours is software plus rented capacity.
Incumbents validate the demand. Our edge is the engine, the B2B shape, and the channel, not their absence.
The data, the channel, and the content that win this market are still unowned.
Each trend alone would be interesting. Together they open a first-mover window: the assets that will decide this category in Spanish are still unowned, and they compound for whoever builds them first.
The longevity wave
Longevity has moved from curiosity to consumer category. Function and Neko raised on it at unicorn valuations; Superpower raised on the same wave.
GLP-1 mainstreaming
Every GLP-1 patient needs labs, metabolic monitoring and structured follow-up: the exact service a metabolic-optimization practice sells.
AI maturity
Frontier models make a physician-led premium practice scalable. The engine already exists and runs in a real practice today.
The compounding window
The B2B assets that decide this category, the clinician channel, the Spanish clinical corpus and the outcomes dataset, are still unowned. Each compounds with time, so the first builder becomes the default everyone else must chase.
First-mover windows close quickly. This one is open today, and every quarter inside it compounds.
The founder's practice funds the proof before investors do, so the platform raises from strength.
Practice-first, sharpened: the founder's UAE practice funds and proves the engine at UAE cash prices, and the platform raises from strength. Every stage is independently profitable and funds the option on the next. You never bet the company. It keeps the ceiling and raises the floor.
Function Health · the asset-light proof
Started with no clinics and no labs, renting Quest's 2,000+ draw sites. Roughly 500,000 members by early 2026, after a $298M Series B at a $2.5B valuation (Nov 2025). Then it bought infrastructure from strength: Ezra (May 2025, the $499 full-body MRI) and Getlabs (Apr 2026, at-home phlebotomy), while building an AI medical-intelligence model on its member data.
Neko Health · the EU premium proof
Clinic-first, European, premium, and no DTC prescription ads. From one Stockholm clinic in 2023 to ~10,000 scans and a 100,000-person waitlist across two clinics; $260M Series B at a $1.8B valuation (Jan 2025). Brand-and-waitlist growth works in Europe. Its proprietary scanners are both its moat and its burden.
Superpower · the raise-first caution
Raised ~$34M at a ~$300M+ valuation, then cut its membership price from $499 to $199, still searching for its market. Raising before proof forces the price down.
Modern Age, then NGM · the sequence proof
Anant Vinjamoori ran Modern Age, a longevity clinic, before building Next Generation Medicine, the platform. Practice first, then platform. This is Longeva's explicit template: the founder's UAE practice proves the engine, the platform is the product.
Longeva runs the winning sequence: the practice generates cash and proof now, and the platform raises from strength later.
Comp figures as publicly reported, late 2025 to mid-2026.
Two engines run from day one: a cash-pay UAE practice and a Spanish-native B2B platform, both asset-light.
No physical clinic, no owned machines, no capex. That is a feature, not a compromise. The richest comp is the asset-light one: Function started with no clinics and no labs, rented its diagnostic capacity, outgrew the capex-heavy comp, and bought its infrastructure later, from strength. Longeva runs the same shape, across two jurisdictions at once.
Engine 1 · The UAE practice (B2C)
A premium cash-pay longevity and metabolic-optimization telehealth practice in Abu Dhabi, run by the DOH-licensed founder. Rented rails: home phlebotomy is commoditized at AED 45-250 per visit, the engine runs UAE-hosted for data localization, and insurance excludes optimization care, so the market is pure cash-pay.
Engine 2 · The B2B platform (SaaS)
The Spanish-native, units-aware engine licensed to longevity, aesthetics and plastic-surgery clinics across Spain and LatAm. Launches as clinician education and decision support on de-identified data, the MDR-prudent posture, designed to minimize MDR exposure until CE marking, with near-zero marginal cost per report.
UAE practice breakeven: a handful of evaluations a month at AED prices (projection).
B2B marginal cost is near zero, so every paying clinic compounds margin (estimate).
Owned: brand, engine, patient relationship, data. Rented: everything with a depreciation schedule.
Care is asynchronous by design: the nurse home draw doubles as in-person verification, the engine drafts, the physician reviews and signs in batched queues, every patient gets a personally recorded video report plus a messaging line with a response inside 24 hours, and a short physician phone call gates first sensitive prescriptions. No scheduled video consults, no no-shows, time-zone-proof, and aligned with the DOH Tele-Medicine Standard: UAE-hosted servers and Malaffi EMR integration.
Two revenue engines from day one, with the cost structure of a software company and the credibility of a physician-led practice.
Our engine reads any country's labs and reasons like a 15-specialist panel.
Built by the founder and already running in his own practice. Paste any blood panel from any country: the engine detects the units, scores every marker against optimal ranges, and returns a branded, editable clinical report. Decision support, never a substitute for clinical judgment.
Metabolic Optimization Scorecard
Marker by marker, scored on optimal ranges, not merely normal ones.
15 specialist lenses, one voice
Endocrinology, cardiology, hepatology and twelve more, consulted internally and delivered as one integrated synthesis.
Evidence-tiered recommendations
Supplement and peptide guidance graded by evidence. The engine never prescribes and never sources.
Red-flag safety net
Findings that need physician attention are escalated, never buried.
Follow-up trajectory mode
Compares panels over time and shows what moved, in the patient's own units.
Branded, editable output
The physician owns the report, edits it, and signs it.
One engine, two jobs: it powers the founder's UAE practice today and ships to Spanish and LatAm clinics as the product now, not later.
We win on owned depth, data, authority, and distribution, not on a regulatory quirk.
Not by outspending the US comps, but on assets we own and they cannot buy quickly: engine depth, a data head start, clinical authority and Spanish-native distribution.
Every stage is profitable and funds the next, so we never bet the company.
The UAE practice and the first design-partner clinics now, a paid B2B launch next, a raise from strength after that, LatAm scale at the top. The ambition of the US comps, with a financing sequence that never bets the company.
Practice + design partners
The UAE practice live and 6-10 design-partner clinics on free Longeva Preop. Cash from the first evaluations, plus the proof: usage, conversion intent, outcomes data.
Paid B2B launch
Academia, Asesores and Plataforma tiers open in Spain, and the UAE practice scales toward its membership ceiling.
Raise from strength
Outside capital only after the metrics gate: practice contribution, free-to-paid conversion, clinic retention, the dataset.
LatAm scale
LatAm rollout, Empresa and white-label tiers, the CE mark, and optional Spain B2C: the rails are already built and the founder is already colegiado.
You never bet the company. Each step is independently profitable and buys the option on the next. The staircase keeps the ceiling and raises the floor.
We raise only after the metrics prove cash, conversion, retention, and data.
Each step opens only when the one below has proven itself. The Stage 3 raise happens from strength, after the two engines have produced four things:
UAE practice contribution positive
The practice covers its variable and fixed base from evaluations and memberships at AED prices (projection threshold).
Design partners convert to paid
A stated threshold: at least half of the 6-10 free-tier design partners convert to paid tiers (projection threshold).
Clinics keep using the engine
Engine usage retention by clinics: reports generated per clinic per month, holding or growing.
A growing outcomes dataset
De-identified marker trajectories across UAE, Spanish and LatAm labs: the raw material of the data moat.
Retention basis: mature concierge-medicine memberships (MDVIP, for example) report roughly 90 percent annual retention, versus roughly 70 to 80 percent in traditional practice. A ~70 percent six-month retention threshold applies to UAE annual-program members and is deliberately conservative (a newer longevity program churns faster than mature concierge); it will be validated against the founder's own practice follow-up rates. A benchmark and a target, not achieved data.
The reverse-Neko move: a physical flagship is a from-strength choice, not a launch cost. The DOH Tele-Medicine Standard lets the telehealth licence nest inside an existing facility licence, including the founder's planned Abu Dhabi clinic. Capex bought from strength, never paid at the gate.
One asset, two revenue lines, already running: the founder's practice and the Spanish-native platform.
Function, Neko and Superpower must own every patient they ever serve. Longeva scales twice, and this is the shape we already run, not a future state: the practice generates cash, proof and data in the UAE, and the platform compounds in Spanish.
Engine 1 · The founder's practice (B2C, UAE)
Premium cash-pay patients in Abu Dhabi at UAE prices. High revenue per member, concierge service, and the daily proving ground for the engine. Generates the cash, the proof and the outcomes data.
Engine 2 · The platform (B2B, Spanish)
The same units-aware engine licensed to clinics across Spain and LatAm: their patients, our intelligence. Landing now with free Longeva Preop, expanding to paid EUR tiers plus a LatAm USD band.
Function is building an AI model on its member data, validating the engine-on-data strategy at scale. Longeva runs the same play, in Spanish, with two engines instead of one.
A surgeon-founder opens the first clinics through peri-operative care, a channel rivals cannot reach.
Land with peri-operative optimization. Expand to longevity. The same units-aware engine ships as a focused module, Longeva Preop, for aesthetic and plastic-surgery clinics, and the founder's own practice is the living demo. Not a separate company: one engine, a second, warmer door.
Land · Longeva Preop
The labs are drawn before surgery anyway, so added patient friction is zero. The engine's existing capabilities map directly: lab analysis, the supplement and medication audit, the red-flag safety net, and a surgical stop list, supplements to pause for bleeding risk plus HbA1c, ferritin, vitamin D and albumin for healing and infection risk.
Expand · Longevity
Aesthetic-surgery clinics are numerous, marketing-savvy and already buy clinical software, and their patients are precisely the longevity demographic: affluent and prevention-minded. Preop is the Trojan horse; the longevity program is the expansion revenue.
A channel no competitor can replicate. The founder is a board-certified plastic surgeon inside the specialty network, SECPRE in Spain: the first design-partner clinics arrive through warm, owned relationships, with his own practice as the living demo.
A free tier priced as acquisition, not giveaway. A capped free allowance of 5 preop reports per clinic per month, then a modest paid price. The free tier is customer-acquisition cost.
The UAE practice has its own warm GTM: the founder's existing premium patient base plus referral. DOH advertising permits are a budgeted overhead, not a blocker.
Stated plainly: decision support, de-identified by default; identifiable patient data only on the Empresa tier under a DPA; the treating clinician retains every decision. CE marking as a Class IIa device is budgeted for the scale stage.
Land with preop, expand to longevity: the warm aesthetic-surgery channel opens the first doors, and the longevity program turns them into recurring revenue.
The founder built the engine, owns the brand, treats the patients, and has the network.
Dr. Miguel Bravo is the physician, the builder of the engine, and the owner of the operating stack.
- ✓Board-certified plastic surgeon (FEBOPRAS) inside the SECPRE network, with an active premium private practice in Abu Dhabi.
- ✓Practicing longevity and metabolic-optimization physician.
- ✓Personally built the clinical AI engine and uses it with his own patients today: the UAE practice is the platform's living showcase.
- ✓Already owns the operating stack: brand system, CRM, marketing site, and a warm patient base to seed the first cohort.
- ✓Dual-jurisdiction physician: colegiado in Spain and DOH-licensed in Abu Dhabi. He practices in Abu Dhabi today and can e-prescribe Spain-wide via REMPe himself, which keeps the documented Spain B2C option open.
- ✓The asynchronous care model fits the founder's calendar: UAE practice breakeven needs roughly 10-15 physician-hours a month of batched, time-zone-independent review, so Longeva runs alongside the surgical practice until the Stage 2 gate.
Open seat: a full-time business and operations co-founder, recruited with this round. The founder runs medicine and product; the co-founder runs growth and operations.
Five owned, compounding assets defend this business, and not one is a law.
Five layers, weighted honestly: the durable ones first, authority, distribution and switching costs, then the engine and the data with their caveats stated plainly. Each is an asset we own, and each compounds with every patient and every quarter.
Clinical authority and brand
A board-certified surgeon-founder who runs the engine on his own patients in a top-tier cash-pay market, plus a planned blinded, physician-rated benchmark: citable proof that a competitor's marketing cannot shortcut.
Owned distribution
The warm aesthetic-surgery channel (the SECPRE network, Longeva Preop) and the Spanish-language clinical content corpus that AI search engines will cite. First-mover content compounds.
Switching costs
Clinics embed Longeva in their workflow, each patient's trajectory history lives in it, and white-label partners build their offering on it. Leaving means starting over.
The engine, stated honestly
A real head start: units-aware depth and a 15-specialist synthesis built by a clinician. But interpretation is commoditizing fast, wearables now bundle blood tests and give AI readings away free, so the durable edge is clinician judgment, the regulated treatment layer they all avoid, and Spanish-native depth no US tool ships.
The data, stated honestly
De-identified scorecard deltas and serial-panel trajectories across UAE, Spanish and LatAm labs: de-identified by default, governed by GDPR consent and DPAs, a research asset today that becomes a moat only at scale. The same flywheel Function Health raised on, earlier on the curve.
None of these depend on a law staying in place. The next slide stress-tests that claim.
Longeva wins in every regulatory scenario, including the ones that hurt rivals.
The fair question for a health business in two regulated jurisdictions: what happens when the rules move? Four scenarios, honest qualitative likelihoods, no invented probabilities.
Status quo
Base case. The rules stay as they are and we execute the staircase as planned. Nothing in the plan requires a change in law.
DTC prescription advertising liberalizes
Very unlikely. The ban is embedded in Directive 2001/83/EC, has held for decades, and was retained in the current EU pharma reform. If it fell, US-style entrants would meet the assets that already compounded: data, brand, channel and corpus. Premium concierge medicine does not compete on ad spend.
Clinic and telehealth rules tighten
Plausible. Spain-side, Longeva is compliance-native: centro sanitario licensing, colegiación, REMPe e-prescribing, GDPR by design. UAE-side, the practice runs DOH-licensed with UAE-hosted servers and Malaffi EMR integration, and nurse-measured vitals at the home draw exceed questionnaire-only telehealth. Tightening removes grey-zone competitors and raises the barrier behind us.
AI and medical-device enforcement tightens
The most plausible shift. The B2B platform holds the MDR-prudent posture from day one: clinician education and decision support, de-identified by default, identifiable data only under a DPA on the Empresa tier. CE marking as a Class IIa device is a real, budgeted cost, an estimated 12 to 24 months, landing at the scale stage. DOH oversight of clinical AI in the UAE is met the same way: the physician signs everything. Tightening converts that compliance into the barrier newcomers cannot afford.
Regulation is a filter we pass, not a wall we hide behind.
Premium cash pricing in the UAE, recurring software pricing in Spanish: two revenue lines from day one.
UAE evaluation (estimates)
Price AED 2,400 founding. Variable cost roughly AED 500-700: lab panel, nurse home draw, AI compute. Stated honestly: the founder is the physician, so physician cost is opportunity cost, not cash. Contribution roughly AED 1,700-1,900 per evaluation, which is why breakeven lands at a handful of evaluations a month.
B2B subscription (estimates)
Gross margin above 85% at scale: marginal cost per report is near zero and the product is support-light by design. The capped free tier is customer-acquisition cost, and the LatAm USD band prices to local purchasing power.
Premium, not mass-market. The UAE practice prices against King's College Hospital Dubai programs at AED 17,500-32,500 (clinic package tiers as quoted, 2026), not against 199 USD consumer subscriptions. The service earns the price: physician time, concierge logistics, depth.
Margin protected by design. Insurance excludes optimization care in the UAE, so there is no payer discount pressure; AI cost per report is metered and capped in both engines.
All prices and unit economics are estimates (projections), to be confirmed in the 90-day validation with the first paying cohort. Founding-cohort pricing steps up to the list prices after the founding cohort closes.
A structured round, first close 150k EUR, hard cap 300k EUR, to productize the platform, launch the UAE practice, and hit the metrics that unlock the seed.
No invented traction, no vanity logos. A 90-day, low-cost validation gates all larger spend: the first paying UAE evaluations, the first 3 signed design-partner clinics on free Preop (Stage 1 target: 6-10), and the benchmark protocol.
Why raise now, not after validation?
Honestly: to de-risk personal capital, to fund a full-time operator co-founder, and to run the UAE practice launch and the B2B productization in parallel, not in sequence. The 90-day gate still decides every euro of larger spend.
What this round buys
A post-money SAFE, relationship-priced, cap set with the lead investor. You buy the B2B platform early and cheap, wrapped in a UAE practice designed to be profitable on its own: an excellent business by itself, but the venture outcome is the platform.
The co-founder package is equity-led with modest or deferred cash; part of this round funds the operator search.
Prove
UAE practice live plus 6-10 design-partner clinics on free Preop: cash, usage and the outcomes dataset.
Productize
Paid B2B launch in Spain (Academia, Asesores, Plataforma) while the UAE practice scales.
Raise, then scale
Raise from strength at the metrics gate; LatAm scale, Empresa and white-label, the CE mark, optional Spain B2C.